Using marginal structural models to analyze randomized clinical trials with non-adherence and lost to follow up
•Unlike the Intention-to-Treat approach, Marginal Structural Models can account for the effects of time-varying treatments in the presence of censoring and time-dependent confounding influenced by prior treatment.•A randomized clinical trial on asthma treatment was used as working model to determine...
Saved in:
Published in | Annals of epidemiology Vol. 63; pp. 22 - 28 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.11.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Unlike the Intention-to-Treat approach, Marginal Structural Models can account for the effects of time-varying treatments in the presence of censoring and time-dependent confounding influenced by prior treatment.•A randomized clinical trial on asthma treatment was used as working model to determine whether the use of Marginal Structural Models to adjust for post-randomization bias would change the results of the original Intention-to-Treat analysis.•Despite the occurrence of non-adherence and censorship, the use of Marginal Structural Models did not change the findings of the original Intention-to-Treat analysis. Our findings are comparable to that of other trials with similar proportions of non-adherence and censorship comparing Marginal Structural Models to Intention-to-Treat.•Because no adherence or censorship thresholds currently exist to assist researchers to determine when Marginal Structural Models may be superior to Intention-to-Treat, Marginal Structural Models are recommended as a sensitivity analysis to the Intention-to-Treat approach in clinical trials with non-adherence and censorship.
In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment.
Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix.
Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21).
Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials. |
---|---|
AbstractList | •Unlike the Intention-to-Treat approach, Marginal Structural Models can account for the effects of time-varying treatments in the presence of censoring and time-dependent confounding influenced by prior treatment.•A randomized clinical trial on asthma treatment was used as working model to determine whether the use of Marginal Structural Models to adjust for post-randomization bias would change the results of the original Intention-to-Treat analysis.•Despite the occurrence of non-adherence and censorship, the use of Marginal Structural Models did not change the findings of the original Intention-to-Treat analysis. Our findings are comparable to that of other trials with similar proportions of non-adherence and censorship comparing Marginal Structural Models to Intention-to-Treat.•Because no adherence or censorship thresholds currently exist to assist researchers to determine when Marginal Structural Models may be superior to Intention-to-Treat, Marginal Structural Models are recommended as a sensitivity analysis to the Intention-to-Treat approach in clinical trials with non-adherence and censorship.
In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment.
Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix.
Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21).
Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials. In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment. Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix. Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21). Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials. In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment.BACKGROUNDIn the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment.Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix.METHODSInverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix.Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21).RESULTSOut of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21).Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials.CONCLUSIONConcordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials. |
Author | Holbrook, Janet Lancet, Elizabeth A. Morabia, Alfredo Borrell, Luisa N. |
Author_xml | – sequence: 1 givenname: Elizabeth A. surname: Lancet fullname: Lancet, Elizabeth A. email: Elizabeth.Lancet13@sphmail.cuny.edu organization: Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York, New York, NY – sequence: 2 givenname: Luisa N. surname: Borrell fullname: Borrell, Luisa N. organization: Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York, New York, NY – sequence: 3 givenname: Janet surname: Holbrook fullname: Holbrook, Janet organization: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD – sequence: 4 givenname: Alfredo surname: Morabia fullname: Morabia, Alfredo organization: Barry Commoner Center for Health and the Environment, Queens College, City University of New York, Flushing, NY |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34289408$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUtv1DAUhS1URB_wFyBLNgl-JXYWCFUVL6kSG7q2HPum9eDYg-1QTX89Hk2HRTd05Svf75xr33OOTkIMgNA7gjuCyfBh0-kQYOssLB3FlHRYdBiTF-iMSMFa2sv-pNaYi5aKUZyi85w3GGMhBX2FThmncuRYnqF4k124bRadbl3QvsklraasqZZLtOBzU2Kja2f3AE3SwcbFPYBtjHfBmUqV5HSl7l25a-ojW23vIEEwUFW28TGXvcMcvY_3zbp9jV7OlYc3j-cFuvny-efVt_b6x9fvV5fXreFUlJaN2lg-UcnthGc5wyTwjIFRQcexXgtGBsnpaGkPowTOzDANtanrD7nWA7tA7w--2xR_r5CLWlw24L0OENesaN9z1nNKWEXfPqLrtIBV2-TqOnbquKQKfDwAJsWcE8zKuKKLi6Ek7bwiWO1DURv1LxS1D0VhoWooVS-e6I8j_q-8PChrEPDHQVLZuP1yrUtgirLRPcPj0xOPY3a_YPcsh79H5MKu |
CitedBy_id | crossref_primary_10_1097_QAD_0000000000004105 |
Cites_doi | 10.1097/MLR.0b013e31806518ac 10.1002/sim.3801 10.1016/j.conctc.2016.10.005 10.1007/s13665-012-0024-y 10.1016/j.jaci.2011.12.986 10.1164/rccm.200603-416OC 10.1001/jama.288.3.321 10.1002/sim.3585 10.1177/2167696815621645 10.2202/1557-4679.1117 10.1177/1740774511420743 10.1093/aje/kwn164 10.1093/aje/kwh131 10.1037/a0022610 10.1002/sim.1144 10.1097/EDE.0b013e3181df1b69 10.1046/j.1365-2125.2002.01628.x 10.1093/biostatistics/kxq054 10.1097/00001648-200009000-00011 10.1093/aje/155.11.1045 |
ContentType | Journal Article |
Copyright | 2021 Elsevier Inc. Copyright © 2021 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2021 Elsevier Inc. – notice: Copyright © 2021 Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.annepidem.2021.07.001 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1873-2585 |
EndPage | 28 |
ExternalDocumentID | 34289408 10_1016_j_annepidem_2021_07_001 S1047279721002052 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 23M 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEH HMK HMO HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OD~ OO0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K UAP WH7 XPP Z5R ~G- AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG LCYCR RIG AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c427t-39acd4b284db0f8feb70f0e327299b2873168429d25e98e43c6b6272a0784aa63 |
IEDL.DBID | .~1 |
ISSN | 1047-2797 1873-2585 |
IngestDate | Fri Jul 11 03:13:06 EDT 2025 Mon Jul 21 05:49:56 EDT 2025 Thu Apr 24 22:53:10 EDT 2025 Tue Jul 01 03:11:40 EDT 2025 Fri Feb 23 02:43:40 EST 2024 Tue Aug 26 20:15:00 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Clinical trials Inverse probability weighting Causalinference Intention to treat Marginal structural models |
Language | English |
License | Copyright © 2021 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c427t-39acd4b284db0f8feb70f0e327299b2873168429d25e98e43c6b6272a0784aa63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 34289408 |
PQID | 2554354213 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2554354213 pubmed_primary_34289408 crossref_citationtrail_10_1016_j_annepidem_2021_07_001 crossref_primary_10_1016_j_annepidem_2021_07_001 elsevier_sciencedirect_doi_10_1016_j_annepidem_2021_07_001 elsevier_clinicalkey_doi_10_1016_j_annepidem_2021_07_001 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2021 2021-11-00 20211101 |
PublicationDateYYYYMMDD | 2021-11-01 |
PublicationDate_xml | – month: 11 year: 2021 text: November 2021 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Annals of epidemiology |
PublicationTitleAlternate | Ann Epidemiol |
PublicationYear | 2021 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Faries, Kadziola (bib0019) 2010 Curtis, Hammill, Eisenstein, Kramer, Anstrom (bib0016) 2007; 45 Sumino, Holbrook, Wise, Rogers (bib0014) 2012; 1 Robins, Hernan (bib0005) 2009 Hernán, Brumback, Robins (bib0007) 2002; 21 Rossouw, Anderson, Prentice, LaCroix, Kooperberg, Stefanick (bib0029) 2002; 288 Toh, Hernandez-Diaz, Logan, Robins, Hernan (bib0028) 2010; 21 Bodnar, Davidian, Siega-Riz, Tsiatis (bib0006) 2004; 159 Rochon, Bhapkar, Pieper, Kraus (bib0012) 2016; 4 Hernán, Robins (bib0018) 2018 Dobson (bib0023) 2002 Zhang, Tsiatis, Davidian, Pieper, Mahaffey (bib0025) 2011; 12 The American Lung Association Asthma Clinical Research (bib0013) 2007; 175 Hernán, Hernández-Díaz (bib0001) 2012; 9 VanderWeele, Hawkley, Thisted, Cacioppo (bib0009) 2011; 79 Twisk (bib0021) 2013 Tepper, Wise, Covar, Irvin, Kercsmar, Kraft (bib0015) 2012; 129 . Fox (bib0022) 2008 Crowson C.S., Schenck L.A., Green A.B., Atkinson E.J., Therneau T.M. The basics of propensity scoring and marginal structural models. Mayo Clinic Technical Report #84, August 1, 2013. Robins, Hernán, Brumback (bib0003) 2000; 11 Hernán, Hernández-Díaz, Robins (bib0004) 2013; 159 (bib0024) 2018 Thoemmes, Ong (bib0020) 2016; 4 Sheiner (bib0002) 2002; 54 Toh, Hernán (bib0010) 2008; 4 Cook, Cole, Hennekens (bib0027) 2002; 155 Shortreed, Forbes (bib0008) 2010; 29 Cole, Hernán (bib0011) 2008; 168 Cain, Cole (bib0026) 2009; 28 The American Lung Association Asthma Clinical Research (10.1016/j.annepidem.2021.07.001_bib0013) 2007; 175 Toh (10.1016/j.annepidem.2021.07.001_bib0010) 2008; 4 Cook (10.1016/j.annepidem.2021.07.001_bib0027) 2002; 155 Shortreed (10.1016/j.annepidem.2021.07.001_bib0008) 2010; 29 VanderWeele (10.1016/j.annepidem.2021.07.001_bib0009) 2011; 79 Twisk (10.1016/j.annepidem.2021.07.001_bib0021) 2013 Hernán (10.1016/j.annepidem.2021.07.001_bib0004) 2013; 159 Hernán (10.1016/j.annepidem.2021.07.001_bib0007) 2002; 21 (10.1016/j.annepidem.2021.07.001_bib0024) 2018 Zhang (10.1016/j.annepidem.2021.07.001_bib0025) 2011; 12 10.1016/j.annepidem.2021.07.001_bib0017 Cain (10.1016/j.annepidem.2021.07.001_bib0026) 2009; 28 Faries (10.1016/j.annepidem.2021.07.001_bib0019) 2010 Thoemmes (10.1016/j.annepidem.2021.07.001_bib0020) 2016; 4 Rochon (10.1016/j.annepidem.2021.07.001_bib0012) 2016; 4 Sumino (10.1016/j.annepidem.2021.07.001_bib0014) 2012; 1 Fox (10.1016/j.annepidem.2021.07.001_bib0022) 2008 Dobson (10.1016/j.annepidem.2021.07.001_bib0023) 2002 Hernán (10.1016/j.annepidem.2021.07.001_bib0018) 2018 Cole (10.1016/j.annepidem.2021.07.001_bib0011) 2008; 168 Tepper (10.1016/j.annepidem.2021.07.001_bib0015) 2012; 129 Hernán (10.1016/j.annepidem.2021.07.001_bib0001) 2012; 9 Toh (10.1016/j.annepidem.2021.07.001_bib0028) 2010; 21 Robins (10.1016/j.annepidem.2021.07.001_bib0003) 2000; 11 Curtis (10.1016/j.annepidem.2021.07.001_bib0016) 2007; 45 Robins (10.1016/j.annepidem.2021.07.001_bib0005) 2009 Rossouw (10.1016/j.annepidem.2021.07.001_bib0029) 2002; 288 Sheiner (10.1016/j.annepidem.2021.07.001_bib0002) 2002; 54 Bodnar (10.1016/j.annepidem.2021.07.001_bib0006) 2004; 159 |
References_xml | – volume: 175 start-page: 235 year: 2007 end-page: 242 ident: bib0013 article-title: Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma publication-title: Am J Respir Crit Care Med – year: 2018 ident: bib0018 article-title: . chapman & hall/crc, forthcoming publication-title: Causal Inference – reference: Crowson C.S., Schenck L.A., Green A.B., Atkinson E.J., Therneau T.M. The basics of propensity scoring and marginal structural models. Mayo Clinic Technical Report #84, August 1, 2013. – year: 2008 ident: bib0022 article-title: . second edi publication-title: Applied regression analysis and generalized linear models – year: 2018 ident: bib0024 article-title: SAS 9.4 publication-title: Copyright © – volume: 12 start-page: 258 year: 2011 end-page: 269 ident: bib0025 article-title: Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial publication-title: Biostatistics – volume: 9 start-page: 48 year: 2012 end-page: 55 ident: bib0001 article-title: Beyond the intention-to-treat in comparative effectiveness research publication-title: Clin Trials – volume: 21 start-page: 528 year: 2010 end-page: 539 ident: bib0028 article-title: Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization publication-title: Epidemiology – volume: 79 start-page: 225 year: 2011 end-page: 235 ident: bib0009 article-title: A marginal structural model analysis for loneliness: implications for intervention trials and clinical practice publication-title: J Consult Clin Psychol – volume: 29 start-page: 431 year: 2010 end-page: 433 ident: bib0008 article-title: Missing data in the exposure of interest and marginal structural models: a simulation study based on the framingham heart study publication-title: Stat Med – volume: 4 start-page: 40 year: 2016 end-page: 59 ident: bib0020 article-title: A primer on inverse probability of treatment weighting and marginal structural models publication-title: Emerging Adulthood – year: 2013 ident: bib0021 article-title: Applied longitudinal data analysis for epidemiology: a practical guide – volume: 11 start-page: 550 year: 2000 end-page: 560 ident: bib0003 article-title: Marginal structural models and causal inference in epidemiology publication-title: Epidemiology – volume: 21 start-page: 1689 year: 2002 end-page: 1709 ident: bib0007 article-title: Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures publication-title: Stat Med – volume: 168 start-page: 656 year: 2008 end-page: 664 ident: bib0011 article-title: Constructing inverse probability weights for marginal structural models publication-title: Am J Epidemiol – volume: 129 start-page: S65 year: 2012 end-page: S87 ident: bib0015 article-title: Asthma outcomes: pulmonary physiology publication-title: J Allergy Clin Immunol – start-page: 553 year: 2009 end-page: 599 ident: bib0005 article-title: Estimation of the causal effects of time-varying exposures publication-title: Longitudinal data analysis – volume: 4 start-page: 222 year: 2016 end-page: 228 ident: bib0012 article-title: Application of the marginal structural model to account for suboptimal adherence in a randomized controlled trial publication-title: Contemp Clin Trials Commun – volume: 159 start-page: 926 year: 2004 end-page: 934 ident: bib0006 article-title: Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology publication-title: Am J Epidemiol – reference: . – volume: 1 start-page: 251 year: 2012 end-page: 258 ident: bib0014 article-title: Asthma clinical trials of American lung association/asthma clinical research centers (ALA-ACRC): what have we learned in 12 years? publication-title: Curr Respir Care Rep – volume: 45 start-page: S103 year: 2007 end-page: S107 ident: bib0016 article-title: Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases publication-title: Med Care – start-page: 211 year: 2010 end-page: 228 ident: bib0019 article-title: Analysis of longitudinal observational data using marginal structural models publication-title: Analysis of Observational Health Care Data Using SAS® – year: 2002 ident: bib0023 article-title: An introduction to generalized linear models – volume: 54 start-page: 203 year: 2002 end-page: 211 ident: bib0002 article-title: Is intent-to-treat analysis always (ever) enough? publication-title: Br J Clin Pharmacol – volume: 4 start-page: Article 22 year: 2008 ident: bib0010 article-title: Causal inference from longitudinal studies with baseline randomization publication-title: Int J Biostat – volume: 28 start-page: 1725 year: 2009 end-page: 1738 ident: bib0026 article-title: Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death publication-title: Stat Med – volume: 159 start-page: 560 year: 2013 end-page: 562 ident: bib0004 article-title: Randomized trials analyzed as observational studies publication-title: Ann Intern Med – volume: 155 start-page: 1045 year: 2002 end-page: 1053 ident: bib0027 article-title: Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians’ Health Study publication-title: Am J Epidemiol – volume: 288 start-page: 321 year: 2002 end-page: 333 ident: bib0029 article-title: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial publication-title: JAMA – year: 2002 ident: 10.1016/j.annepidem.2021.07.001_bib0023 – volume: 45 start-page: S103 issue: 10 Supl 2 year: 2007 ident: 10.1016/j.annepidem.2021.07.001_bib0016 article-title: Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases publication-title: Med Care doi: 10.1097/MLR.0b013e31806518ac – volume: 29 start-page: 431 issue: 4 year: 2010 ident: 10.1016/j.annepidem.2021.07.001_bib0008 article-title: Missing data in the exposure of interest and marginal structural models: a simulation study based on the framingham heart study publication-title: Stat Med doi: 10.1002/sim.3801 – year: 2008 ident: 10.1016/j.annepidem.2021.07.001_bib0022 article-title: Applied regression analysis and generalized linear models. second edi – start-page: 211 year: 2010 ident: 10.1016/j.annepidem.2021.07.001_bib0019 article-title: Analysis of longitudinal observational data using marginal structural models – volume: 4 start-page: 222 year: 2016 ident: 10.1016/j.annepidem.2021.07.001_bib0012 article-title: Application of the marginal structural model to account for suboptimal adherence in a randomized controlled trial publication-title: Contemp Clin Trials Commun doi: 10.1016/j.conctc.2016.10.005 – volume: 1 start-page: 251 issue: 4 year: 2012 ident: 10.1016/j.annepidem.2021.07.001_bib0014 article-title: Asthma clinical trials of American lung association/asthma clinical research centers (ALA-ACRC): what have we learned in 12 years? publication-title: Curr Respir Care Rep doi: 10.1007/s13665-012-0024-y – volume: 129 start-page: S65 issue: 3 Suppl year: 2012 ident: 10.1016/j.annepidem.2021.07.001_bib0015 article-title: Asthma outcomes: pulmonary physiology publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2011.12.986 – year: 2018 ident: 10.1016/j.annepidem.2021.07.001_bib0024 article-title: SAS 9.4 publication-title: Copyright © – volume: 175 start-page: 235 issue: 3 year: 2007 ident: 10.1016/j.annepidem.2021.07.001_bib0013 article-title: Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200603-416OC – start-page: 553 year: 2009 ident: 10.1016/j.annepidem.2021.07.001_bib0005 article-title: Estimation of the causal effects of time-varying exposures – volume: 288 start-page: 321 year: 2002 ident: 10.1016/j.annepidem.2021.07.001_bib0029 article-title: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial publication-title: JAMA doi: 10.1001/jama.288.3.321 – volume: 28 start-page: 1725 issue: 12 year: 2009 ident: 10.1016/j.annepidem.2021.07.001_bib0026 article-title: Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death publication-title: Stat Med doi: 10.1002/sim.3585 – volume: 4 start-page: 40 issue: 1 year: 2016 ident: 10.1016/j.annepidem.2021.07.001_bib0020 article-title: A primer on inverse probability of treatment weighting and marginal structural models publication-title: Emerging Adulthood doi: 10.1177/2167696815621645 – volume: 4 start-page: Article 22 issue: 1 year: 2008 ident: 10.1016/j.annepidem.2021.07.001_bib0010 article-title: Causal inference from longitudinal studies with baseline randomization publication-title: Int J Biostat doi: 10.2202/1557-4679.1117 – volume: 9 start-page: 48 issue: 1 year: 2012 ident: 10.1016/j.annepidem.2021.07.001_bib0001 article-title: Beyond the intention-to-treat in comparative effectiveness research publication-title: Clin Trials doi: 10.1177/1740774511420743 – volume: 168 start-page: 656 issue: 6 year: 2008 ident: 10.1016/j.annepidem.2021.07.001_bib0011 article-title: Constructing inverse probability weights for marginal structural models publication-title: Am J Epidemiol doi: 10.1093/aje/kwn164 – volume: 159 start-page: 926 issue: 10 year: 2004 ident: 10.1016/j.annepidem.2021.07.001_bib0006 article-title: Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology publication-title: Am J Epidemiol doi: 10.1093/aje/kwh131 – volume: 79 start-page: 225 issue: 2 year: 2011 ident: 10.1016/j.annepidem.2021.07.001_bib0009 article-title: A marginal structural model analysis for loneliness: implications for intervention trials and clinical practice publication-title: J Consult Clin Psychol doi: 10.1037/a0022610 – volume: 21 start-page: 1689 issue: 12 year: 2002 ident: 10.1016/j.annepidem.2021.07.001_bib0007 article-title: Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures publication-title: Stat Med doi: 10.1002/sim.1144 – volume: 21 start-page: 528 year: 2010 ident: 10.1016/j.annepidem.2021.07.001_bib0028 article-title: Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization publication-title: Epidemiology doi: 10.1097/EDE.0b013e3181df1b69 – volume: 159 start-page: 560 issue: 8 year: 2013 ident: 10.1016/j.annepidem.2021.07.001_bib0004 article-title: Randomized trials analyzed as observational studies publication-title: Ann Intern Med – volume: 54 start-page: 203 issue: 2 year: 2002 ident: 10.1016/j.annepidem.2021.07.001_bib0002 article-title: Is intent-to-treat analysis always (ever) enough? publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.2002.01628.x – year: 2013 ident: 10.1016/j.annepidem.2021.07.001_bib0021 – volume: 12 start-page: 258 issue: 2 year: 2011 ident: 10.1016/j.annepidem.2021.07.001_bib0025 article-title: Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial publication-title: Biostatistics doi: 10.1093/biostatistics/kxq054 – year: 2018 ident: 10.1016/j.annepidem.2021.07.001_bib0018 article-title: Causal inference. chapman & hall/crc, forthcoming – volume: 11 start-page: 550 issue: 5 year: 2000 ident: 10.1016/j.annepidem.2021.07.001_bib0003 article-title: Marginal structural models and causal inference in epidemiology publication-title: Epidemiology doi: 10.1097/00001648-200009000-00011 – ident: 10.1016/j.annepidem.2021.07.001_bib0017 – volume: 155 start-page: 1045 issue: 11 year: 2002 ident: 10.1016/j.annepidem.2021.07.001_bib0027 article-title: Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians’ Health Study publication-title: Am J Epidemiol doi: 10.1093/aje/155.11.1045 |
SSID | ssj0007872 |
Score | 2.3497941 |
Snippet | •Unlike the Intention-to-Treat approach, Marginal Structural Models can account for the effects of time-varying treatments in the presence of censoring and... In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 22 |
SubjectTerms | Causalinference Clinical trials Humans Intention to treat Intention to Treat Analysis Inverse probability weighting Lost to Follow-Up Marginal structural models Models, Structural Patient Compliance Randomized Controlled Trials as Topic |
Title | Using marginal structural models to analyze randomized clinical trials with non-adherence and lost to follow up |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1047279721002052 https://dx.doi.org/10.1016/j.annepidem.2021.07.001 https://www.ncbi.nlm.nih.gov/pubmed/34289408 https://www.proquest.com/docview/2554354213 |
Volume | 63 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA9jgggiOr_mFxF8rWvT9Mu3MRxT2V50sLeQLClOtnW4DWEP_u1ekrYyUCb42LTXtMnlPpK73yF0AyY2TxMSOokrhUMjIZxYKVh4XhoTTocB9XVycrcXdvr0cRAMKqhV5MLosMpc9luZbqR13tLIR7MxG40azxpkgEQafUbbPIGWw5RGmstvP7_DPIAhSYlIAE-vxXhxkGWmECs4isQzKJ55dZgfNNRvFqjRRO19tJebkLhpv_IAVdS0hra7-SF5De3arThsM4wOUWbCAvCEv5sSWNhCxmq4DWzq4MzxIsNcg5OsFAbVJbPJaKUkLpImsansMcd6yxZPs6nD5atNEgQqicfZfKHfkAJHZR94OTtC_fb9S6vj5HUWnCEl0cLxEz6UVICiksJN41SJyE1d5RMwvBNoNsWtQG9JEqgkVjB7oQjhJofBpZyH_jGqQu_qFGEVqSgWHKh4DKZJwpWk0pOJCMAt9JRXR2ExtmyYg5DrWhhjVkSbvbFyUpieFObqA3IgdEvCmcXh2EwSF5PHihEDwchAV2wmvStJ17jxb8TXBacwWKv6AIZPVbacM3DfwDqlxPPr6MSyUPkzPviBCXXjs_90fY529JXNlbxAVeAndQlG00JcmVVxhbaaD0-d3hc2tBfh |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dT9RAEJ8gJmpCiKIo-LUm-liv3W6_THgwKDmE40VIeFt3b6fhCFwv9giBB_4p_0FnP1pCosHE8NrNtNvZ2d_M7M4HwHsysVVd8TyqYqMjUWgdlYi08ZK65EqMM5Ha5OTRXj48EN8Os8MF-NXlwtiwyoD9HtMdWocng8DNwWwyGXy3RQZ4YavPWJsn4yGycgcvzslvaze2v9Aif-B86-v-5jAKrQWiseDFPEorNTZCEzYbHddljbqI6xhTTrZmRY9dPyeCasMzrEqkCec6p0FFGlUolaf03ntwXxBc2LYJH6-u40poB_C-BAJN70ZQmSLwdJ1fyTPliSsbGtrR_EEl_s3kdapv6zEsB5uVffZseQILOF2BB6NwK78CS_7sj_mUpqfQuDgEdqp-up5bzNeotfU9mGu807J5w5SthnKJjHSlaU4nl2hYl6XJXCuRltkzYjZtppEyRz4rkagMO2nauX1DTSLcnLOz2TM4uBPur8IifR1fAMMCi1IrolIl2UKVQiNMYiqdkR-aYLIGecdbOQ5Vz23zjRPZhbcdy35RpF0UGdsbeSKMe8KZL_xxO0nZLZ7sOEZILEk53U76qSe9If7_RvyukxRJ4GBvfNQUm7NWkr9I5rDgSboGz70I9T-TkuNZibhc_59Pv4WHw_3Rrtzd3tt5CY_siE_UfAWLJFv4miy2uX7jdgiDH3e9JX8D8eJSRw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Using+marginal+structural+models+to+analyze+randomized+clinical+trials+with+non-adherence+and+lost+to+follow+up&rft.jtitle=Annals+of+epidemiology&rft.au=Lancet%2C+Elizabeth+A.&rft.au=Borrell%2C+Luisa+N.&rft.au=Holbrook%2C+Janet&rft.au=Morabia%2C+Alfredo&rft.date=2021-11-01&rft.pub=Elsevier+Inc&rft.issn=1047-2797&rft.eissn=1873-2585&rft.volume=63&rft.spage=22&rft.epage=28&rft_id=info:doi/10.1016%2Fj.annepidem.2021.07.001&rft.externalDocID=S1047279721002052 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1047-2797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1047-2797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1047-2797&client=summon |